This trial is not actively recruiting.

This trial has completed recruitment on this platform, and is no longer accepting new referrals.

An Epstein-Barr Virus (EBV) vaccine clinical trial

Trial ID: NCT05164094
A clinical trial conducted by Moderna is evaluating an investigational vaccine that may protect people from Epstein-Barr Virus (EBV), which can cause Infectious Mononucleosis, commonly referred to as “mono”. Mono is a common cause of fever, fatigue, sore throat, and enlarged lymph nodes, and can result in prolonged symptoms, like tiredness, as well as hospitalization.

Trial Details

The Eclipse Trial is evaluating the safety and immune response of an investigational vaccine, called mRNA-1189, that may protect against mono. Participation in the Eclipse Trial lasts approximately 18 months, including a 28-day screening period, a six-month dosing period, and up to 11 months of follow-up observation.

Each year in the United States, there are approximately 500 cases of mono per 100,000 persons. Mono disproportionately affects adolescents and young adults from 15 to 24 years of age. There are currently no approved vaccines to protect against EBV and mono.

Estimated Enrollment

272 Participants



Eligibility Criteria

Participants must:

  • Be between 18 and 30 years old
  • Be in generally good health, with any chronic conditions well-controlled

Participants must not:

  • Have participated in another trial within a month of the Screening Visit
  • Be pregnant or breastfeeding at the time of Screening or be planning to breastfeed at any time while enrolled in the trial

Site Locations

You will need to travel to one of the study sites taking part in this clinical trial.

Sites are located in the cities/states identified with the red pin:

What to Expect

Participation in the Eclipse Clinical Trial lasts approximately 18 months and includes phone calls, telemedicine visits, and up to fifteen visits to the study site.

  • Participants will be given three injections in the upper arm. Participants have a chance of receiving either the mRNA-1189 investigational vaccine or a placebo. By using a placebo, medical researchers are able to understand if the investigational vaccine is effective in protecting against mono.
  • Participants will be asked to return to the study site for follow up visits and will also have telemedicine visits with the clinical trial doctor to monitor for any symptoms. During these phone calls, the doctor and medical staff will check how you are feeling and ask for updates on your health.
  • Participants will be asked to use an eDiary app on their smartphones or a provided smartphone to report any symptoms they might experience after their injection.
  • Participants will be closely monitored by the clinical research team if any symptoms are reported at any time throughout participation.

Insurance is not needed to join this clinical trial, and compensation for participants’ time will be available.

Frequently Asked Questions (FAQs)